Early trials of Ebola vaccine show immune responseBMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h1844 (Published 08 April 2015) Cite this as: BMJ 2015;350:h1844
- Susan Mayor
Small, phase I trials in Africa and Europe of an experimental vaccine against Ebola virus disease have shown an immune response in all of the healthy adults vaccinated, preliminary results reported in the New England Journal of Medicine have shown.1
The Zaire variant candidate vaccine rVSV-ZEBOV uses live recombinant vesicular stomatitis virus (rVSV), a livestock disease that generally causes no or only mild illness in humans, to carry DNA from Zaire ebolavirus with the aim of stimulating …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial